Acarbose and Miglitol are both α-glucosidase inhibitors. Acarbose is a bit better in terms of glucose-lowering effect, but at the same time, the side effects of Acarbose are also more obvious, and the patients will suffer from abdominal distension, diarrhea, etc. Miglitol is more gentle than Acarbose, and has less side effects. Miglitol is more moderate and has fewer side effects than Acarbose, and the use of these drugs should be under the guidance of a physician. Acarbose indications are with dietary control, for the treatment of type 2 diabetes mellitus as well as to reduce postprandial glucose in people with impaired glucose tolerance, compared with Miglitol to lower the effect of glucose is stronger, the dosage is swallowed as a whole immediately before a meal or chewed with the first few mouthfuls of food, and the dosage varies from person to person. At the same time, the side effects of acarbose are also more obvious, patients will experience abdominal distension, diarrhea and so on. It is contraindicated in children, pregnant women and patients with liver insufficiency. Miglitol, also used as a hypoglycemic drug, has a more moderate action and fewer side effects than Acarbose, but some individual patients may experience bloating and diarrhea. It is contraindicated for those who are allergic to the components of the drug, patients with inflammatory bowel disease or intestinal obstruction. The use of the above two drugs needs to be combined with the actual situation, the use of the doctor’s guidance, not to decide on their own which drug to use to avoid adverse reactions.